Diamyd’s Phase III study in Europe now approved in all nine countries
Diamyd Medical announces today that the European Phase III study with the diabetes vaccine Diamyd® has now been approved in all nine of the planned European countries.Diamyd Medical’s Phase III study in Europe includes a total of 320 patients in nine countries, and aims to evaluate the Diamyd® vaccine’s effect in preserving the insulin producing capacity in children and adolescents with recent-onset type 1 diabetes. In Phase II studies, the vaccine has been shown to either halt or slow the autoimmune destruction process and preserve the remaining insulin production. “Approvals in the major